Novel therapies for cancer patients can come with a more complex development path. More defined target patient populations are often needed and harder to find. The landscape of early phase oncology drug development is evolving, adding more pressure on study timelines and mitigating risks. IQVIA has end-to-end solutions in early phase oncology to help sponsors to adapt to the paradigm shift.
IQVIA's Early Phase Oncology Network (EPON) is a global network of qualified Phase I oncology sites working in close alignment for fast site activation and better patient recruitment. By utilizing pre-identified experienced sites, site selection timelines can be reduced, increasing operational efficiencies.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
